U.S. scientists discovered a faulty signaling pathway for the peroxisome proliferator-activated receptor-y protein that appears to aggravate cystic fibrosis. They found that targeting the defective pathway with the drug rosiglitazone, which binds and turns on PPAR-y, resulted in normal gene expression and improved survival for mice with the inherited lung condition.

Full Story:

Related Summaries